ReviewBiological psychiatry2020
Capturing Novel Non-opioid Pain Targets.
Review in Biological psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 97 citations in OpenAlex.
- Efficacy of intraoperative systemic lidocaine on quality of recovery after laparoscopic colorectal surgery: a randomized controlled trial.Annals of medicine · 2024Trial
- Review
- A synergistic nanozyme platform breaking the neuroinflammatory-oxidative stress cycle for extended pain relief.International journal of pharmaceutics: X · 2026Article
- Clinical Efficacy and Risks of Clonidine Infusion for Sedation and Analgesia: A Narrative Review.Current pain and headache reports · 2026Review
- Intravenous galanin (1-16) and a GalR1 agonist attenuate allodynia in rats with spared nerve injury.Pain reports · 2026Article
- A comprehensive review on pain: Model, target, therapy, and prospect (Review).International journal of molecular medicine · 2026Review
- Gallic acid exerts therapeutic effects on sciatica by reducing inflammatory responses through the regulation of NOX4-mediated oxidative stress.Frontiers in immunology · 2026Article
- Article
- Emphasizing the Pharmacological Potentials of the Methanolic Extract ofVeterinary medicine international · 2026Article
- NKG2D receptor ligands are cell surface biomarkers for injured murine and human nociceptive sensory neurons.Journal of neuroinflammation · 2025Article
- Article
- Decoding Pain: Next-Generation In Vitro Systems for Mechanistic Insights and Drug Discovery.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Article
- An approach to targeting Nav1.7 for pain sensations.The Journal of clinical investigation · 2025Article
- Mimicking opioid analgesia in cortical pain circuits.bioRxiv : the preprint server for biology · 2025Article
- From a clinically relevant pain target to a possible analgesic treatment strategy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Editorial: Pharmacological advances to treat pathological pain.Frontiers in pharmacology · 2025Article
- Phytochemical-based therapeutics from traditional eastern medicine: analgesic effects and ion channel modulation.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
- Directions for analgesic development.Journal of anesthesia and translational medicine · 2024Review
- A Comprehensive Collection of Pain and Opioid Use Disorder Compounds for High-Throughput Screening and Artificial Intelligence-Driven Drug Discovery.ACS pharmacology & translational science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The relatively high efficacy of opioids, which have associated risks of addiction, tolerance, and dependence, for the management of acute and terminal pain has been a major driver of the opioid crisis, together with the availability, overprescription, and diversion of these drugs. Eliminating opioids without an effective replacement is, however, no solution, as it substitutes one major problem with another. To deal successfully with the opioid crisis, we need to discover novel analgesics whose mechanisms do not involve the mu opioid receptor but that have high analgesic potency and low risk of adverse effects, particularly no abuse liability. The question is how to achieve this. There are several necessary elements; first, we need to understand the nature of pain and the mechanisms responsible for it, and second, we need to adopt novel and unbiased approaches to the identification and validation of pain targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.